{'52WeekChange': 0.68840575,
 'SandP52WeekChange': 0.0644362,
 'address1': '3980 Premier Drive',
 'address2': 'Suite 310',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.41,
 'askSize': 1300,
 'averageDailyVolume10Day': 231275,
 'averageVolume': 439069,
 'averageVolume10days': 231275,
 'beta': -1.829012,
 'beta3Year': None,
 'bid': 2.32,
 'bidSize': 800,
 'bookValue': -1.384,
 'category': None,
 'circulatingSupply': None,
 'city': 'High Point',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.44,
 'dayLow': 2.31,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.952,
 'enterpriseToRevenue': 87.106,
 'enterpriseValue': 161233840,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '336 841 0310',
 'fiftyDayAverage': 2.473457,
 'fiftyTwoWeekHigh': 4.23,
 'fiftyTwoWeekLow': 1.23,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 9791217,
 'forwardEps': -0.59,
 'forwardPE': -3.9491525,
 'fromCurrency': None,
 'fullTimeEmployees': 26,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.76633,
 'heldPercentInstitutions': 0.01988,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vtvtherapeutics.com',
 'longBusinessSummary': 'vTv Therapeutics Inc., a clinical-stage '
                        'biopharmaceutical company, discovers and develops '
                        'orally administered small molecule drug candidates to '
                        'fill unmet medical needs. The company is developing '
                        'Azeliragon, an orally administered, small molecule '
                        'antagonist targeting the receptor for advanced '
                        'glycation end products, which is in Phase II clinical '
                        "trials for the treatment of mild Alzheimer's disease. "
                        'It is also developing TTP399, an orally administered, '
                        'liver-selective glucokinase activator that has '
                        'completed Phase II clinical trials to treat type 2 '
                        'diabetes, as well as is in Phase II/III clinical '
                        'trials for treating type 1 diabetes; and TTP273, an '
                        'orally administered, non-peptidic agonist that '
                        'targets the glucagon-like peptide-1 receptor, which '
                        'has completed Phase II clinical trials for the '
                        'treatment of type 2 diabetes. In addition, the '
                        'company is developing HPP737, HPP971, and HPP3033 for '
                        'the treatment of chronic disease. It has a license '
                        'agreement with Reneo Pharmaceuticals, Inc. to develop '
                        'and commercialize peroxisome proliferation activated '
                        'receptor delta agonist program, including the '
                        'compound HPP593. vTv Therapeutics Inc. also has '
                        'license and research agreements with Hangzhou '
                        'Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara '
                        'Biopharma Co., Ltd.; JDRF International; Novo Nordisk '
                        'A/S; and Columbia University. The company was founded '
                        'in 2015 and is headquartered in High Point, North '
                        'Carolina. vTv Therapeutics Inc. is a subsidiary of '
                        'MacAndrews & Forbes Incorporated.',
 'longName': 'vTv Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 159343328,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_304063261',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -16754000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.44,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '336 841 0300',
 'previousClose': 2.44,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 86.085,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.44,
 'regularMarketDayLow': 2.31,
 'regularMarketOpen': 2.44,
 'regularMarketPreviousClose': 2.44,
 'regularMarketPrice': 2.44,
 'regularMarketVolume': 167444,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45293500,
 'sharesPercentSharesOut': 0.0307,
 'sharesShort': 2099733,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1785177,
 'shortName': 'vTv Therapeutics Inc.',
 'shortPercentOfFloat': 0.1901,
 'shortRatio': 3.18,
 'startDate': None,
 'state': 'NC',
 'strikePrice': None,
 'symbol': 'VTVT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.473,
 'twoHundredDayAverage': 2.433892,
 'volume': 167444,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vtvtherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '27265'}